Farmacia Hospitalaria y Farmacogenómica

Villanueva-Bueno, C; Escudero-Vilaplana, V; Collado-Borrell, R; Gimenez-Manzorro, A; Ribed, A; Marzal-Alfaro, B; Revuelta-Herrero, JL; Gonzalez-Haba, E; Herranz, A; Sanjurjo, M.

Medication guide for the perioperative management of oral antineoplastic agents in cancer patients

Expert Opinion On Drug Safety. 2022; 21(1): 107-119 Nº de citas: 6 [doi:10.1080/14740338.2021.1965990]

Gomez-Centurion, I; Oarbeascoa, G; Garcia, MC; Fresnena, MCL; Carreno, MJM; Vilaplana, VE; Gonzalez-Haba, E; Bailen, R; Dorado, N; Juarez, LM; Macias, GR; Lopez, PF; Encinas, C; Bastos-Oreiro, M; Anguita, J; Sanjurjo, M; Diez-Martin, JL; Kwon, M.

Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility

INTERNATIONAL JOURNAL OF HEMATOLOGY. 2022; 115(1): 61-68 Nº de citas: 15 [doi:10.1007/s12185-021-03219-2]

Vicente-Valor, J; Escudero-Vilaplana, V; Collado-Borrell, R; Perez-Ramirez, S; Villanueva-Bueno, C; Narrillos-Moraza, A; Garcia-Sanchez, S; Beamud-Cortes, M; Herranz, A; Sanjurjo, M.

Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice

Expert Opinion on Drug Metabolism & Toxicology. 2022; 17(12): 1467-1473 Nº de citas: 11 [doi:10.1080/17425255.2021.2027908]

Martinez, CLC; Jimenez, RMR; Vazquez-Lopez, C; Perez-Cordon, L; Hidalgo, SV; Jose, PB.

Recommendations for using oral antineoplastic and immunomodulating agents in oncohematology by enteral tube administration

Nutricion Hospitalaria. 2022; 39(1): 171-201 Nº de citas: 6 [doi:10.20960/nh.03736]

Soria-Chacartegui, P; Villapalos-Garcia, G; Lopez-Fernandez, LA; Navares-Gomez, M; Mejia-Abril, G; Abad-Santos, F; Zubiaur, P.

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study

Pharmaceutics. 2021; 13(12): Nº de citas: 10 [doi:10.3390/pharmaceutics13122036]

GARCÍA, X.; SALVADOR, S..

Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?

Journal of Personalized Medicine. 2021; : [doi:https://doi.org/10.3390/jpm11111180]

Salvador-Martin, S; Melgarejo-Ortuno, A; Lopez-Fernandez, LA.

Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease

Pharmaceutics. 2021; 13(11): Nº de citas: 4 [doi:10.3390/pharmaceutics13111786]

García-González X; Salvador-Martín S.

Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?

Journal of Personalized Medicine. 2021; 11(11): Nº de citas: 6 [doi:10.3390/jpm11111180]

Morillo Verdugo R; Calvin Lamas M; Delgado Latorre ATJ; Ferrando Piqueres R; Fernández-Llamazares CM; Negro Vega E; Tortajada Goitia B.

Development of the Q-PEX standard for quality certification of pharmaceutical care for outpatients of Pharmacy services

Journal of Healthcare Quality Research. 2021; 36(6): 324-332 Nº de citas: 16 [doi:10.1016/j.jhqr.2021.03.010]

SALVADOR, S.; MELGAREJO, A.; LOPEZ, L..

Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease

Pharmaceutics. 2021; 13(11): [doi:https://doi.org/10.3390/pharmaceutics13111786]

GIL, S.; CARBONELL, D.; LOPEZ, L.; MIGUENS, I.; ALONSO, R.; BUÑO, I.; Muñoz, P.; Ochando Cano, Jordi; PION, M.; CORREA, R..

Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days

Frontiers in Immunology. 2021; 12: 726960-726960 Nº de citas: 24 [doi:10.3389/fimmu.2021.726960]

Amor-Garcia, MA; Fernandez-Llamazares, CM; Manrique-Rodriguez, S; Narrillos-Moraza, A; Garcia-Morin, M; Huerta-Aragones, J; Sanjurjo-Saez, M.

Bromocriptine for the treatment of postoperative cerebellar mutism syndrome in pediatric patients: Three case reports

JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2021; 27(7): 1753-1757 Nº de citas: 11 [doi:10.1177/1078155220982046]

Nieto-Gonzalez, JC; Trives-Folguera, L; Melgarejo-Ortuno, A; Ais, A; Serrano-Benavente, B; Sanjurjo, M; Alvaro-Gracia, JM; Saez, IM.

Persistence and adherence to biologic therapies in juvenile idiopathic arthritis

Scientific Reports. 2021; 11(1): 16195-16195 Nº de citas: 6 [doi:10.1038/s41598-021-95252-8]

Escudero-Vilaplana, V; Collado-Borrell, R; del Monte-Millan, M; Hoyo-Munoz, A; Martinez-Sagrera, PG; Revuelta-Herrero, JL; Marzal-Alfaro, B; Gonzalez-Haba, E; Cobo, SLT; Gilarranz, YJ; Herranz, A; Sanjurjo, M; Martin, M.

Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice

SUPPORTIVE CARE IN CANCER. 2021; 29(8): 4673-4681 Nº de citas: 1 [doi:10.1007/s00520-021-06016-z]

Villalvazo, P; Marzal-Alfaro, B; Garcia-Alfonso, P; Revuelta-Herrero, JL; Thomas, F; Lopez-Tarruella, S; Garcia-Gonzalez, X; Calvo, A; Yakoubi, M; Salvador-Martin, S; Lopez-Lopez, F; Aguilar, I; Sanjurjo-Saez, M; Martin, M; Lopez-Fernandez, LA.

DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach

Journal of Personalized Medicine. 2021; 11(8): Nº de citas: 7 [doi:10.3390/jpm11080792]

Souza-Neto, FV; Jimenez-Gonzalez, S; Delgado-Valero, B; Jurado-Lopez, R; Genty, M; Romero-Miranda, A; Rodriguez, C; Nieto, ML; Martinez-Martinez, E; Cachofeiro, V.

The Interplay of Mitochondrial Oxidative Stress and Endoplasmic Reticulum Stress in Cardiovascular Fibrosis in Obese Rats

Antioxidants. 2021; 10(8): Nº de citas: 33 [doi:10.3390/antiox10081274]

Escudero-Vilaplana, V; Collado-Borrell, R; Villanueva-Bueno, C; Alvarez, R; Herranz, A; Sanjurjo, M.

Acute pancreatitis in a patient treated with imatinib and gefitinib

JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2021; 27(4): 980-983 Nº de citas: 3 [doi:10.1177/1078155220949639]

Ibanez-Garcia, S; Zatarain-Nicolas, E; Garcia-Gonzalez, X; Rodriguez-Ferrero, ML; Fernandez-Yanez, J; Diaz, FJFA; Saez, MS.

Levels of tacrolimus after treatment for chronic hepatitis C with direct antiviral agents in solid organ transplant recipients

International Journal of Clinical Pharmacy. 2021; 43(3): 731-736 Nº de citas: 2 [doi:10.1007/s11096-020-01162-6]